CD274 and neoplasm: Recent clinical applications in cancers have shown that by blocking the interaction of PD-1 and PD-L1, antibodies may unlock activated tumor-reactive T cells and induce a durable antitumor response (Topalian et al., 2012), suggesting that this axis plays a critical role in tumor immunosuppression.